VIVUS INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2009-12-29: Form 8-K; Period of report 2009-12-29; Description 8.01 Other Events; Details 8.01.
- 2009-11-24: Form 8-K; Period of report 2009-11-18; Description 8.01 Other Events; Details 8.01.
- 2009-11-18: Form 8-K; Period of report 2009-11-18; Description 8.01 Other Events; Details 8.01.
- 2009-11-17: Form 8-K; Period of report 2009-11-17; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2009-12-29 | 8-K | 2009-12-29 | 8.01 Other Events | 8.01 On December 29, 2009, VIVUS, Inc. issued a press release titled “VIVUS Submits Qnexa New Drug Application to the FDA for the Treatment of Obesity.” A copy of the press release is attached hereto as Exhibit 99.1. | a09-37054_18k.htm |
| 2009-11-24 | 8-K | 2009-11-18 | 8.01 Other Events | 8.01 On November 18, 2009, VIVUS, Inc. conducted a conference call and webcast discussion of avanafil Phase 3 results. | a09-34214_18k.htm |
| 2009-11-18 | 8-K | 2009-11-18 | 8.01 Other Events | 8.01 On November 18, 2009, VIVUS, Inc. issued a press release titled “VIVUS Announces Positive Results From Phase 3 Study of Avanafil in Erectile Dysfunction; Data Demonstrate Robust Efficacy, Favorable Side-Effect Profile.” A copy of the press release is attached hereto as Exhibit 99.1. | a09-33735_18k.htm |
| 2009-11-17 | 8-K | 2009-11-17 | 8.01 Other Events | 8.01 On November 17, 2009, VIVUS, Inc. issued a press release titled “VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results.” A copy of the press release is attached hereto as Exhibit 99.1. | a09-33735_28k.htm |
| 2009-11-13 | 8-K | 2009-11-11 | 8.01 Other Events | 8.01 On November 11, 2009, VIVUS, Inc. issued a press release titled “VIVUS to Present at Lazard Capital Markets Healthcare Conference.” A copy of the press release is attached hereto as Exhibit 99.1. | a09-33567_18k.htm |
| 2009-11-06 | 8-K | 2009-11-03 | 2.02 Results of Operations and Financial Condition; 8.01 Other Events | 2.02 On November 3, 2009, VIVUS, Inc. conducted a conference call during which members of its senior management team discussed financial results for the third quarter ended September 30, 2009 and certain other information. 8.01 On November 5, 2009, VIVUS, Inc. issued a press release titled “VIVUS to Present at Merriman Curhan Ford’s Investor Summit.” A copy of the press release is attached hereto as Exhibit 99.2. | a09-33080_18k.htm |
| 2009-11-03 | 8-K | 2009-10-30 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 2.02 On November 3, 2009, VIVUS, Inc. (the “Company”) issued a press release regarding its financial results for the third quarter ended September 30, 2009 and certain other information. 5.02 On October 30, 2009, the Company’s Board of Directors (the “Board”) appointed Peter Tam, age 45, to the position of President and as a member of the Board. 5.03 (a) In connection with Mr. Tam’s appointment as a director, the Board amended and restated the Company’s bylaws to increase the authorized number of directors of the Company from six to seven, effective immediately. | a09-32771_18k.htm |
| 2009-11-02 | 8-K | 2009-10-29 | 8.01 Other Events | 8.01 On October 29, 2009, VIVUS, Inc. issued a press release titled “Additional Data from the Qnexa Phase 3 Studies Presented at The Obesity Society 27th Annual Scientific Meeting.” A copy of the press release is attached hereto as Exhibit 99.1. | a09-32572_18k.htm |
| 2009-10-26 | 8-K | 2009-10-24 | 8.01 Other Events | 8.01 On October 24, 2009, Dr. Wesley Day, Vice President of Clinical Development at VIVUS, Inc. (the “Company”), presented data from the Company’s two year long phase 3 obesity trials at the 27th Annual Scientific Meeting of The Obesity Society in Washington, D.C. A copy of Dr. Day’s slide presentation from the meeting is attached hereto as Exhibit 99.1. | a09-32185_18k.htm |
| 2009-09-18 | 8-K | 2009-09-17 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a09-26706_18k.htm |
| 2009-09-14 | 8-K | 2009-09-09 | 8.01 Other Events | 8.01 On September 9, 2009, VIVUS, Inc. conducted a conference call and webcast discussion of Qnexa Phase 3 results. | a09-26185_18k.htm |
| 2009-09-09 | 8-K | 2009-09-09 | 8.01 Other Events | 8.01 As previously announced, on September 9, 2009 at 8:00 a.m. | a09-25664_18k.htm |
| 2009-09-09 | 8-K | 2009-09-09 | 8.01 Other Events | 8.01 On September 9, 2009, VIVUS, Inc. issued a press release titled “VIVUS Announces Positive Results from Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities.” A copy of the press release is attached hereto as Exhibit 99.1. | a09-25664_38k.htm |
| 2009-09-08 | 8-K | 2009-09-08 | 8.01 Other Events | 8.01 On September 8, 2009, VIVUS, Inc. issued a press release titled “VIVUS to Host Conference Call and Webcast Discussion of Qnexa Phase 3 Results.” A copy of the press release is attached hereto as Exhibit 99.1. | a09-25664_28k.htm |
| 2009-09-03 | 8-K | 2009-09-01 | 8.01 Other Events | 8.01 On September 1, 2009, VIVUS, Inc. issued a press release titled “VIVUS to Present at Four Upcoming Healthcare Conferences.” A copy of the press release is attached hereto as Exhibit 99.1. | a09-25455_18k.htm |
| 2009-08-17 | 8-K | 2009-08-11 | 2.02 Results of Operations and Financial Condition | 2.02 On August 11, 2009, VIVUS, Inc. conducted a conference call during which members of its senior management team discussed financial results for the second quarter ended June 30, 2009 and certain other information. | a09-23282_18k.htm |
| 2009-08-11 | 8-K | 2009-08-11 | 2.02 Results of Operations and Financial Condition | 2.02 On August 11, 2009, VIVUS, Inc. issued a press release regarding its financial results for the second quarter ended June 30, 2009 and certain other information. | a09-22350_18k.htm |
| 2009-07-15 | 8-K/A | 2008-12-19 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a09-18161_18ka.htm |
| 2009-05-11 | 8-K | 2009-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2009, VIVUS, Inc. issued a press release regarding its financial results for the first quarter ended March 31, 2009 and certain other information. | a09-12609_18k.htm |
| 2009-04-09 | 8-K | 2009-04-06 | 8.01 Other Events | 8.01 VIVUS, Inc., or the Company, and Acrux Limited through its wholly owned subsidiary FemPharm Pty Ltd., or Acrux, are parties to the Testosterone Development and Commercialization Agreement dated February 12, 2004, or the Testosterone Agreement. | a09-9658_18k.htm |
| 2009-03-19 | 8-K | 2009-03-16 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | a09-8118_18k.htm |
| 2009-03-11 | 8-K | 2009-03-09 | 2.02 Results of Operations and Financial Condition | 2.02 On March 9, 2009, VIVUS, Inc. (the “Company”) conducted a conference call during which members of its senior management team discussed financial results for the fourth quarter and year ended December 31, 2008 and certain other information. | a09-7507_18k.htm |
| 2009-03-09 | 8-K | 2009-03-09 | 2.02 Results of Operations and Financial Condition | 2.02 On March 9, 2009, VIVUS, Inc. issued a press release regarding the results of its operations for the fourth quarter and year ended December 31, 2008 and certain other information. | a09-7306_18k.htm |
| 2009-02-11 | 8-K | 2009-02-10 | 8.01 Other Events | 8.01 On February 10, 2009, VIVUS, Inc. issued a press release titled “VIVUS Initiates Second Pivotal Phase 3 Trial of Avanafil for Treatment of Erectile Dysfunction.” A copy of the press release is attached hereto as Exhibit 99.1. | a09-5300_18k.htm |
| 2009-02-03 | 8-K | 2009-02-02 | 8.01 Other Events | 8.01 On February 2, 2009, VIVUS, Inc. issued a press release titled “VIVUS to Present at the 11th Annual BIO CEO & Investor Conference.” A copy of the press release is attached hereto as Exhibit 99.1. | a09-4488_18k.htm |
| 2009-01-29 | 8-K | 2009-01-23 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Entry into a Material Definitive Agreement. 5.02 On January 23, 2009, the Company appointed Peter Tam to the position of Chief Operating Officer. | a08-31128_18k.htm |
| 2009-01-13 | 8-K | 2009-01-12 | 8.01 Other Events | 8.01 On January 12, 2009, VIVUS, Inc. issued a press release titled “Qnexa Treatment Results in Improved Glucose Control in Obese Non-Diabetic Subjects.” A copy of the press release is attached hereto as Exhibit 99.1. | a09-3003_18k.htm |
| 2009-01-07 | 8-K | 2009-01-06 | 8.01 Other Events | 8.01 On January 6, 2009, VIVUS, Inc. issued a press release titled “VIVUS to Present at the 2009 JP Morgan Healthcare Conference.” A copy of the press release is attached hereto as Exhibit 99.1. | a08-31128_28k.htm |